22nd May 2012 Oslo, Norway.  NattoPharma today announces the presentation of the recently completed milestone 3-year clinical trial investigating beneficial effects of nutritional doses of natural vitamin K2 (MenaQ7®) on bone and vascular health.
At Geneva’s Vitafoods 2012, Dr. Cees Vermeer, Principal Investigator at VitaK laboratory at Maastricht University, has presented data showing significant benefits for improved bone strength and prevention of cardiovascular aging with daily supplementation of MenaQ7.

In the study, 244 healthy postmenopausal women received for 3 years daily 180 µg K2 from MenaQ7 or a placebo. The clinical measurements included bone mineral density, bone strength, vascular characteristics by ultrasound and pulse-wave velocity (PWV), the latter evaluating age-related stiffening of blood vessels.

MenaQ7 supplementation provided a statistically significant protection of the most vulnerable bone structures i.e. vertebrae and the hip. One of the important...